Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002253 · ClinicalTrials.gov registry record · NA
A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.
A NA study, sponsored by Sandoz.
- Completed
- Registry status
- NA
- Development phase
NCT00002253: Completed NA study, sponsored by Sandoz.
NCT00002253 is a NA study that has completed, run by Sandoz. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002253, a NA study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The primary objective of this study is to determine the relapse rate in patients with AIDS-related diarrhea who were found to be "Responders" in a previous placebo-controlled, double-blind study of Sandostatin (Study #D203 - FDA 102A). The secondary objectives include: 1) To evaluate clinical efficacy and safety of open-label Sandostatin in patients who were "Non-Responders" in Study #D203 - FDA 102A; 2) To evaluate the efficacy and safety of Sandostatin during prolonged open-label treatment in "Responders" from Study #D03 - FDA 102A.
Interventions
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002253 record still lists
NCT00002253 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Octreotide is the first listed.
NCT00002253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002253 about?
NCT00002253 is a clinical study titled "A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.". The primary objective of this study is to determine the relapse rate in patients with AIDS-related diarrhea who were found to be "Responders" in a previous placebo-controlled, double-blind study of Sandostatin (Study #D203 - FDA 102A). The secondary objectives include: 1) To evaluate clinical effic...
What is the current status of trial NCT00002253?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002253?
The interventions under investigation include: Octreotide (DRUG).
Who is sponsoring clinical trial NCT00002253?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.